Immunoadsorption
From MEpedia, a crowd-sourced encyclopedia of ME and CFS science and history
Immunoadsorption is the technique by which pathogenic substances, especially undesirable antibodies, are removed from blood plasma. Immunoadsorption is considered to have fewer adverse effects than the use of therapeutic plasma exchange.[1] Several medical conditions, such as multiple sclerosis[2] and chronic inflammatory demyelinating polyneuropathy (CIDP)[3] may use immunoadsorption as part of their medical regimen.
Theory[edit | edit source]
A number of studies have found that a subset of ME/CFS patients have abnormal autoantibodies in their blood; immunoadsorption could be used to remove these autoantibodies with the aim of improving symptoms or potentially curing ME/CFS in those patients.[4]
Evidence[edit | edit source]
- 2018, Immunoadsorption to remove ß2 adrenergic receptor antibodies in Chronic Fatigue Syndrome CFS/ME[4] (Full Text)
Clinicians[edit | edit source]
Risks and safety[edit | edit source]
Costs and availability[edit | edit source]
Learn more[edit | edit source]
- Wikipedia page for Immunoadsorption
- 2018, Hope for an ME/CFS Autoimmune Subset: A German Researcher Steps Forward (Carmen Scheibenbogen)
See also[edit | edit source]
References[edit | edit source]
- ↑ Pham, Huy P.; Schwartz, Joseph (2013), "Chapter 79 – Immunoadsorption", Transfusion Medicine and Hemostasis: 525–527, doi:10.1016/B978-0-12-397164-7.00079-3
- ↑ Journal of Neuroinflammation (2012) 9:80. https://doi.org/10.1186/1742-2094-9-80
- ↑ Chapter 23 - Treatment of chronic inflammatory demyelinating polyradiculoneuropathy, Handbook of Clinical Neurology Volume 115, 2013, Pages 415-427, https://doi.org/10.1016/B978-0-444-52902-2.00023-0
- ↑ 4.0 4.1 Scheibenbogen C, Loebel M, Freitag H, Krueger A, Bauer S, Antelmann M, et al. (2018) Immunoadsorption to remove ß2 adrenergic receptor antibodies in Chronic Fatigue Syndrome CFS/ME. PLoS ONE 13(3): e0193672. https://doi.org/10.1371/journal.pone.0193672
